Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 12/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.47 |
| ▸ | BACE1 | P56817 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6679498 | 1.00 | ADRB3 (0.47) | ADRB3ADRB1BACE1KDM4EHSD17B10 | |
| SCHEMBL6683336 | 0.94 | ADRB3 (0.42) | ADRB3ADRB1BACE1 | |
| SCHEMBL6804694 | 0.94 | ADRB3 (0.42) | ADRB3ADRB1BACE1 | |
| SCHEMBL6803309 | 0.93 | ADRB3 (0.41) | ADRB3ADRB1BACE1 | |
| SCHEMBL6681897 | 0.93 | ADRB3 (0.41) | ADRB3ADRB1BACE1 | |
| SCHEMBL6804733 | 0.93 | ADRB3 (0.41) | ADRB3ADRB1BACE1KDM4EMEN1 | |
| SCHEMBL6677024 | 0.93 | ADRB3 (0.41) | ADRB3ADRB1BACE1KDM4EMEN1 | |
| SCHEMBL6676378 | 0.93 | BACE1 (0.40) | ADRB3ADRB1BACE1 | |
| SCHEMBL6803505 | 0.93 | BACE1 (0.40) | ADRB3ADRB1BACE1 | |
| SCHEMBL6680781 | 0.92 | ADRB1 (0.47) | ADRB3ADRB1BACE1SLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | ADRB3 150/4885ADRB1 39/4885BACE1 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.